MAP
SAGE

Madison Avenue Partners’s Sage Therapeutics SAGE Stock Holding History

Madison Avenue Partners’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,077,065
Closed -$55.4M – 27
2025
Q2 		$55.4M Buy
6,077,065
+1,599,267
+36% +$11.8M 3.7% 9
2025
Q1 		$35.6M Buy
+4,477,798
New +$32.8M 3.02% 11

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Madison Avenue Partners's SAGE Position: Q3 2025 in Review

Madison Avenue Partners sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 6,077,065 shares — an estimated $55.4M sold.

Madison Avenue Partners first reported a position in SAGE in Q1 2025 and held it in 2 quarters. The position peaked at $55.4M in Q2 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Madison Avenue Partners reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Madison Avenue Partners sold 6,077,065 Sage Therapeutics shares in Q3 2025, an estimated $55.4M.
  • Madison Avenue Partners first reported a position in Sage Therapeutics in Q1 2025 and held it in 2 quarters.
  • Madison Avenue Partners's Sage Therapeutics position peaked at $55.4M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Madison Avenue Partners's 13F filing for Q3 2025, filed 14 Nov 2025.